Jinghua Pharma: Use Capital Markets To Modernize Chinese Medicine
This article was originally published in PharmAsia News
Executive SummaryJinghua Pharma listed its initial public offering on the Shenzhen Stock Exchange Feb. 3, and it hopes to use the capital to further develop Chinese Medicine in China
You may also be interested in...
Nearly 500 shipments of illegal and unapproved prescription drugs and combination medical devices were seized at US borders thanks to Operation Broadsword.
Sanofi follows Janssen in teaming up with HHS' BARDA to develop a COVID-19 vaccine; using technology platform of its Flublok vaccine, Sanofi expects to enter clinical trials in 1 to 1 ½ years.
Biotech licenses drug composition patents from University of Alaska Fairbanks for study in several disease states. Gilead seeks long-acting HIV therapy or prevention with broadly neutralizing antibodies discovered by Rockefeller U.